anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Directions for connecting the ADDITIVE SOLUTION FORMULA 3 (AS-3) bag to the apheresis device.

Automated RBC additive solution procedures:

Connect ADDITIVE SOLUTION FORMULA 3 (AS-3) after the collection is over and the donor is disconnected. For automated addition of the product, the system will prompt you to connect the bag.

  1. Remove the overwrap by pulling down at notch, and remove the AS-3 bag.
  2. Before use, perform the following checks:
     * Ensure that the solution is the ADDITIVE SOLUTION FORMULA 3 (AS-3) and is within the expiration date.
     * Inspect the bag in good light. Do not use if the container is damaged, leaking or if there is any visible sign of deterioration. Check for leaks by gently squeezing the bag. If leaks are found, discard the bag.
     * Inspect the solution in good light. Use only if solution is clear and free of particulate matter. Bags showing cloudiness, haze, or particulate matter should not be used.
     * Protect from sharp objects.
  3. Remove the protective cap from the port on the bag.
  4. Connect the bag to the apheresis device tubing set using aseptic technique and hang the solution.
  5. Break the frangible connector. When you break frangible connectors, bend them in both directions to ensure that you break them completely. Failure to do so may result in restricted flow.
  6. Proceed according to the apheresis device operator's manual.



Manual RBC additive solution procedures:

Connect ADDITIVE SOLUTION FORMULA 3 (AS-3) after the collection is over and the donor is disconnected.

  1. Seal the RBC product lines as close to the cassette as possible.
  2. Remove the overwrap by pulling down at notch, and remove the ADDITIVE SOLUTION FORMULA 3 bag.
  3. Before use, perform the following checks:
     * Ensure that the solution is the ADDITIVE SOLUTION FORMULA 3 (AS-3) and is within the expiration date.
     * Inspect the bag in good light. Do not use if the container is damaged, leaking or if there is any visible sign of deterioration. Check for leaks by gently squeezing the bag. If leaks are found, discard the bag.
     * Inspect the solution in good light. Use only if solution is clear and free of particulate matter. Bags showing cloudiness, haze, or particulate matter should not be used.
     * Protect from sharp objects.
  4. Remove the protective cap from the port on the bag.
  5. Connect the bag to the apheresis device tubing set using aseptic technique and hang the solution.
  6. Break the frangible connector. When you break frangible connectors, bend them in both directions to ensure that you break them completely. Failure to do so may result in restricted flow.
  7. Proceed according to the apheresis device operator's manual.
Hair Stimulating Complex will be injected intradermally into the scalp of the test subject at 2 timepoints (Baseline and 6 Weeks after Baseline) using sterile syringes with 30 gauge needles at a volume of 0.1 mL per injection. A total of 8 injections (about 3mm apart) will be administered into one of the the 2 randomized sites (left or right) of the subject's scalp. Six weeks after the Baseline injection, the same treatment site will receive a repeat dose (the same volume and number of injections as used in the baseline) with no crossover.
Metastatic melanoma, a highly lethal form of skin cancer, presents significant clinical challenges due to limited therapeutic options and high metastatic capacity. Recent studies have demonstrated that cancer dissemination can occur earlier, before the diagnosis of the primary tumor. The progress in understanding the kinetics of cancer dissemination is limited by the lack of animal models that accurately mimic disease progression. We have established a xenograft model of human melanoma that spontaneously metastasizes to lymph nodes and lungs. This model allows precise monitoring of melanoma progression and is suitable for the quantitative and qualitative analysis of circulating tumor cells (CTCs). We have validated a flow cytometry-based protocol for CTCs enumeration and isolation. We could demonstrate that (i) CTCs were detectable in the bloodstream from the fourth week after tumor initiation, coinciding with the lymph node metastases appearance, (ii) excision of the primary tumor accelerated the formation of metastases in lymph nodes and lungs as early as one-week post-surgery, accompanied by the increased numbers of CTCs, and (iii) CTCs change their surface protein signature. In summary, we present a model of human melanoma that can be effectively utilized for future drug efficacy studies.
The invention belongs to the field of traditional Chinese medicines and health foods, in particular to compound brewing-resistance glossy ganoderma tea with an antifatigue action and a preparation method and application thereof. The invention aims to provide a brand-new antifatigue compound prepared by taking glossy ganoderma as a main component and matching the glossy ganoderma with various traditional Chinese medicines. The compound brewing-resistance glossy ganoderma tea comprises the glossy ganoderma, bighead atractylodes rhizome, endothelium corneum gigeriae galli, rehmannia, dogwood andjasmine. The invention also provides the compound brewing-resistance glossy ganoderma tea. The preparation method comprises the following steps of: by taking a gelatinous substance made of pea starchas a carrier, adding water to decoct active components by using a conventional method, merging water decoctions and concentrating and then packaging into the gelatinous carrier to prepare the brewing-resistance tea. The tea can be brewed repeatedly with hot boiled water, has the advantages of brewing resistance, transparent and clear tea soup, faint scent and sweetness and is portable and is convenient to drink. People feel relived in intestines and stomachs, enhanced in appetite and good in sleeping quality and then feel high in spirits, are not easy to fatigue and powerful all over the body.
Plectin is a cytoskeletal linker of intermediate filaments, encoded by the PLEC gene. Recently, plectin mutations have been identified in a pair of siblings with progressive familial intrahepatic cholestasis. Here, we reported two unrelated infants with plectinopathy causing cholestatic jaundice with novel variants in the PLEC gene. Trio exome sequencing identified compound heterozygous variants in the PLEC gene for each patient: c.71-11768C>T and c.4331G>T (p.Arg1444Leu) in Patient 1, and c.592C>T (p.Arg198Trp) and c.4322G>A (p.Arg1441His) in Patient 2. Immunofluorescence staining of liver samples from both patients revealed scattered signals of plectin in the cytoplasm of hepatocytes and reduced colocalization of plectin and cytokeratin 8. This study not only underscores the involvement of plectin in cholestasis but also highlights the utility of exome sequencing as a powerful diagnostic tool in identifying genetic underpinnings of infantile cholestasis.
Pulsed Radiofrequency This group will receive one dose of intra-articular PRF in the affected knee using previous literature standards. This includes standard blood pressure monitoring, sterile preparation, and needle insertion of the PRF probe directed at the site of maximal pain. The RFG-3C Plus radiofrequency generator will be activated at 42C, pulse width 10ms, and 2Hz frequency for 15 min.
The intervention consists of a total of 18 moderate-to-high intensity aerobic interval training sessions (20-30 minutes/session) spread over a maximum of eight weeks (2-3 times/week) as shown in Table 1. The training sessions are performed on bicycle ergometers (Kettler) and supervised by physiotherapists. Each session is built up by brief periods of high-intensity aerobic exercise (70-80 %) separated by recovery periods of lower-intensity (40-50%). Each session is introduced by a 5-minute warm-up and ends with a 5-minute cool-down (equivalent to 40-50% watt max). The absolute exercise intensity/workload (watt) is determined individually for each participant based on the watt max test performed at baseline.
Recruit up to 70 subjects whom participated in protocol TPX-100-1. The opposing knee that was treated will be getting 200mg in 4 weekly injections. The knee that was treated in TPX-100-1 will get randomized to either 200mg dose or a placebo lookalike. The investigators will follow these subjects for 6 months. Two MRIs of bi-lateral knees will be assessed. Also collection of ADA samples at 4 time points through the 6 month period.
The present invention relates to novel connective tissue related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as 'connective tissue antigens', and the use of such connective tissue antigens for detecting disorders of connective tissue(s), particularly the presence of cancer and cancer metastases. More specifically, isolated connective tissue associated nucleic acid molecules are provided encoding novel connective tissue associated polypeptides. Novel connective tissue polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human connective tissue associated polynucleotides and/or polypeptides. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to connective tissue(s), including cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonsits of polynucleotides and polypeptides of the invention. The present invention further relates to methods and/or compositions for inhibiting the production and function of the polypeptides of the present invention.
FIELD: medicine, virology. SUBSTANCE: invention relates to materials and methods used for suppression of hepatitis C virus (but not hepatitis A and B viruses) infection spreading. Invention proposes polypeptides showing antigenic properties of hepatitis C virus and their fragments. Invention proposes the diagnostic reagent for detection of antibodies raised to hepatitis C virus, set for detection of antibodies raised to hepatitis C virus including diagnostic reagent and method of detection of antibodies raised to hepatitis C virus. Invention ensures to obtain reliable and prognostic agents used for assay of nucleic acids, antigens and antibodies associated with hepatitis C virus. EFFECT: polypeptide indicated above, improved method of detection of antibodies. 30 cl, 73 dwg, 19 tbl
In order to evaluate the efficacy of the addition of a VR body exposure component to the usual treatment, a randomized controlled clinical trial will be conducted. 54 patients with a primary diagnosis of anorexia nervosa and a BMI \> 18.5 will be randomly assigned to the experimental group receiving VR body exposure in addition to cognitive behavioral therapy or control group, which receives cognitive behavioral therapy only. Data regarding eating disorder symptomatology and body related attention will be collected before and at the end of the intervention, as well as after six months of follow-up. In the systematic and hierarchical VR body exposure intervention, which consists of 5 weekly exposure sessions, patients will gradually be exposed to increases in the BMI of their virtual avatar. Each session starts by inducing illusory feelings of ownership over the virtual body by the means of visuo-tactile and visuo-motor stimulation. Then patients are exposed to their virtual bodies in order to achieve the habituation or extinction of the anxiety response to their body image and, consequently, reduce the fear of gaining weight. During exposure, patients will be asked to focus on different parts of the virtual body, by asking what they think and feel about them. Body ownership illusion, body-related anxiety and fear of gaining weight will be assessed within each session by means of visual analogue scales.
The purpose of this study is to assess the efficacy and safety of a staged treatment regimen in Wegener's granulomatosis and related vasculitides in which patients will receive glucocorticoid plus cyclophosphamide at disease onset; cyclophosphamide will be switched to methotrexate upon disease remission. At the current time, cyclophosphamide plus glucocorticoids are the standard of care for the treatment of these disorders. Although this regimen has brought about a marked improvement in survival rate, it has been associated with significant toxicity. Methotrexate plus glucocorticoids have recently been investigated in patients with non life-threatening disease and while this regimen appears to have less toxicity than standard therapy it may be associated with a higher rate of disease relapse. By inducing patients with cyclophosphamide and glucocorticoids then switching to methotrexate at remission, we hope to combine the efficacy of cyclophosphamide with the more favorable toxicity profile of methotrexate. If successful, this regimen could provide a safer, yet effective therapeutic option which would be applicable to all patients regardless of disease severity. In this study, patients will be initially treated with cyclophosphamide and glucocorticoids and then switched from cyclophosphamide to methotrexate upon quiescence of disease activity. If at the end of two full years of methotrexate therapy there is continued evidence of disease remission, the drug will be tapered and ultimately discontinued. Patients will be prospectively monitored for evidence of disease activity and drug toxicity. Specific parameters that will be obtained include the time to disease remission, the rate and time of disease relapse, and the incidence of drug related adverse effects. This study will be open to patients with systemically active Wegener's granulomatosis or related vasculitis regardless of their degree of disease severity.
OBJECTIVE: Aim: To study the impact of bariatric interventions on changes in the parameters of the intestinal microbiome.
PATIENTS AND METHODS: Materials and Methods: The research method is a prospective observational cohort monocentric study. 112 patients were included in the study. All patients had indications for surgical obesity treatment due to IFSO criteria. All patients were offered surgical treatment. 53 patients who consented to the operation formed the study group. 59 patients who refused surgical treatment formed the control group. The result of the study was evaluated one year after the start of treatment. The studied group of patients underwent bariatric interventions. The control group consisted of 59 obese patients who were treated conservatively.
RESULTS: Results: evaluating criteria was: %EWL (percentage of excess weight loss), comorbidity regression, life quality improvement. Overwhelming majority of surgically treated patients with gut microbiome composition improvement reached %EWL≥50. Patients who didn't have improvements in gut microbiota composition had insufficient efficacy of surgical treatment.
CONCLUSION: Conclusions: 1) Surgical treatment of obesity leads to the positive changes in the gut microbiota. 2) Operated patients, who had positive dynamics in changes of gut microbiota demonstrated sufficient efficacy of surgical treatment due to %EWL. 3) Firmicutes/Bacteriodetes ratio and Bacterioidetes/Faecalibacterium ratio can be one of the criteria of the efficacy of surgical treatment of obesity. 4) Patients of the control group, had positive dynamics of changes in gut microbiota much rarely than operated patients and the effectiveness of obesity treatment was insufficient.
Rare diseases and conditions have thus far received relatively less attention in the field of precision/personalized medicine than common chronic diseases. There is a dire need for orphan drug discovery and therapeutics in ways that are informed by the precision/personalized medicine scholarship. Moreover, people with rare conditions, when considered collectively across diseases worldwide, impact many communities. In this overarching context, Activin A Receptor Type 1 (ACVR1) is a transmembrane kinase from the transforming growth factor-β superfamily and plays a critical role in modulating the bone morphogenetic protein signaling. Missense variants of the ACVR1 gene result in modifications in structure and function and, by extension, abnormalities and have been predominantly linked with two rare conditions: fibrodysplasia ossificans progressiva and diffuse intrinsic pontine glioma. We report here an extensive bioinformatic analyses assessing the pool of 50,951 variants and forecast seven highly destabilizing mutations (R206H, G356D, R258S, G328W, G328E, R375P, and R202I) that can significantly alter the structure and function of the native protein. Protein-protein interaction and ConSurf analyses revealed the crucial interactions and localization of highly deleterious mutations in highly conserved domains that may impact the binding and functioning of the protein. cBioPortal, CanSAR Black, and existing literature affirmed the association of these destabilizing mutations with posterior fossa ependymoma, uterine corpus carcinoma, and pediatric brain cancer. The current findings suggest these deleterious nonsynonymous single nucleotide polymorphisms as potential candidates for future functional annotations and validations associated with rare conditions, further aiding the development of precision medicine in rare diseases.
INTRODUCTION: Cervical cancer, a malignancy caused by infection with oncogenic human papillomavirus, disproportionally affects women from low resource settings. Persistence of human papillomavirus infection may mediate an association between tobacco use and cervical cancer. In limited resource settings, women from indigenous communities are often marginalized and do not benefit from evidence-based interventions to prevent tobacco use or cervical cancer due to the limited reach of mainstream healthcare services to these communities. This study determined the association between smoking and high-risk human papillomavirus infection among women from indigenous communities in western Botswana.
METHODS: A cross-sectional study of women in indigenous communities was conducted between June and October 2022. Demographic, clinical and self-reported smoking data were collected. Cervical cytology and HPV DNA testing for high-risk human papillomavirus genotypes were performed. Multilevel multivariable logistic regression models were fit to evaluate the association between smoking and high-risk human papillomavirus infection while adjusting for potential confounders.
RESULTS: A total of 171 participants with a median (interquartile range) age of 40 (31-50) years from three settlements and two villages were recruited for the study. Of these, 17% were current smokers, 32.8% were living with HIV and high-risk human papillomavirus DNA was detected in 32.8% of the cervical specimens. Women who were current smokers, were nearly twice as likely to have cervical high-risk human papillomavirus infection compared to non-smokers (Adjusted Odds Ratio (95% CI); 1.74(1.09, 2.79)) after controlling for confounders.
CONCLUSION: These data underscore the need for effective tobacco control to help mitigate cervical cancer risk in this setting. These findings can help inform decisions about targeted cervical cancer prevention and tobacco cessation interventions for women from indigenous communities.
<P>PROBLEM TO BE SOLVED: To inexpensively provide an arthritis therapeutic agent which is capable of effectively curing arthritis such as rheumatoid arthritis and the like and which has a small fear of side effects.  <P>SOLUTION: This arthritis therapeutic agent includes a microRNA (miRNA) and a stabilizer. Preferably, the stabilizer is atelo collagen. Preferably, a rheumatoid arthritis therapeutic agent is as an miRNA, a synthetic miRNA-15a, a synthetic miRNA-146 or a synthetic miRNA-34a. miRNA is protected with the stabilizer and is taken into over a wide range of synovial membrane tissues without decomposition. The miRNA dosed decomposes directly messenger RNA (mRNA), which undergoes a protein-translation to the gene to cause arthritis, or inhibits a protein translation of mRNA, consequently leads to the cell death of synovial membrane cells to thereby permit the cure of the arthritis.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The invention belongs to the field of medicaments, and particularly relates to a gastrointestinal tract administration medicament for ischemic and hypoxic brain injury and application thereof in preparing medicaments for preventing and treating the ischemic and hypoxic brain injury. The gastrointestinal tract administration medicine for ischemic and hypoxic brain injury contains fisetin as main active ingredient, and further contains catalpolide. When the medicaments are used in combination, the weight ratio of fisetin to catalpolide in the medicament for gastrointestinal tract administration used for ischemic and hypoxic brain injury is as follows: 17-25 parts of fisetin and 6-12 parts of catalpol. The gastrointestinal administration for ischemic and hypoxic brain injury is preferably an oral liquid formulation so that it can be intubated in a patient's involuntary state. The medicine of the invention has certain improvement effect on the behavioral function of ischemic and hypoxic brain injury. Wherein the effect of the combination administration of the fisetin and the catalpol is better than that of the single use of the fisetin.
LBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly). To enable patients to undergo cardiac monitoring, all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles. Patients with objective response or stable disease after re-evaluation at week 8 will continue LBH589 at the same dose until disease progression, unacceptable toxicity and/or at the discretion of the investigator.
Neck pain and injuries are growing healthcare burdens with women having a higher incidence rate and poorer treatment outcomes than males. A better understanding of sex differences in neck biomechanics, foundational for more targeted, effective prevention or treatment strategies, calls for more advanced subject-specific musculoskeletal modeling. Current neck musculoskeletal models are based on generic anatomy, lack subject specificity beyond anthropometric scaling, and are unable to accurately reproduce neck strengths exhibited in vivo without arbitrary muscle force scaling factors or residual torque actuators. In this work, subject-specific neck musculoskeletal models of 23 individuals (11 male, 12 female) were constructed by integrating multi-modality imaging and biomechanical measurements. Each model simulated maximal voluntary neck static exertions in three postures: neck flexion in a neutral posture, flexion in a 40° extended posture, and extension in a 40° flexed posture. Quantitative model validation showed close agreement between model-predicted muscle activation and EMG measurement. The models unveiled that (1) males have greater moment arms in one flexor muscle group and five extensor muscle groups, (2) females exhibited higher cervical spinal compression per unit exertion force in the flexed posture, and (3) the variability of compression force was much greater in females in all three exertions but most notably in the extension with a flexed "dropped head" position. These insights illuminated a plausible pathway from sex differences in neck biomechanics to sex disparities in the risk and prevalence of neck pain.